Back to
2021–2025 indicators
In 2021, we launched a new strategy with ambitious goals and targets.
Our 2021–2025 strategy
In 2021, we launched a new strategy with ambitious goals and targets.
Our 2021–2025 strategyMission indicators
- M.1 Under-five mortality rate
- M.2 Future deaths averted with Gavi support
- M.3 Future disability-adjusted life years (DALYs) averted with Gavi support
- M.4 Reduction in zero-dose children
- M.5 Unique children immunised through routine immunisation with Gavi support
- M.6 Economic benefits generated through Gavi-supported immunisations
EQUITY GOAL STRATEGY INDICATORS
- S2.1 Geographic equity of third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) coverage
- S2.2 DTP drop-out
- S2.3 Coverage of first dose of measles-containing vaccine (MCV1)
- S2.4 Immunisation sessions conducted
- S2.5 Stock availability at facility level
- S2.6 Expanded Programme on Immunization (EPI) management capacity
- S2.7 Implementation of tailored plans to overcome demand-related barriers
- S2.8 Addressing gender-related barriers to immunisation
HEALTHY MARKETS GOAL STRATEGY INDICATORS
- S4.1 Healthy market dynamics
- S4.2 Incentivise innovations
- S4.3 Scale up innovations
VACCINE GOAL STRATEGY INDICATORS
- S1.1 Breadth of protection
- S1.2 Vaccine coverage
- Third dose of diphtheria-tetanus-pertussis (DTP)-containing vaccine (DTP3)
- Second dose of measles-containing vaccine (MCV2)
- Last dose in schedule of pneumococcal conjugate vaccine (PCV3)
- Last dose in schedule of human papillomavirus vaccine (HPVC)
- S1.3 Rate of scale-up of new vaccines
- Last dose in schedule of pneumococcal conjugate vaccine (PCV3)
- Last dose in schedule of rotavirus vaccine (RotavirusC)
- Second dose of measles-containing vaccine (MCV2)
- Yellow fever vaccine
- S1.4 Vaccine introductions
- S1.5 Country prioritisation of vaccines
- S1.6 Measles campaign reach
- S1.7 Timely detection of and response to outbreaks
SUSTAINABILITY GOAL STRATEGY INDICATORS
- S3.1 Co-financing fulfilment
- S3.2 Preventing backsliding in Gavi-transitioned countries
- S3.3 Vaccine introductions in Gavi-transitioned countries and never Gavi-eligible countries
Related documents
Our 2021–2025 strategy
In June 2019, the Gavi Board approved a new five-year strategy (“Gavi 5.0”) with a vision of “Leaving no one behind with immunisation” and a mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines…
